A randomized, controlled, multicenter phase III study of the efficacy and safety of Rituximab (RTX) monotherapy versus thebest available treatment in patients with mixedcryoglobulinemia syndrome, on behalf of the rituximab studygroup in cryoglobulinemic sindrome.